ACELRX PHARMACEUT. DL-01 (R5XA) - Total Liabilities
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has total liabilities worth €12.68 Million EUR (≈ $14.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ACELRX PHARMACEUT. DL-01 (R5XA) equity growth momentum to track the company's year-over-year net asset growth rate.
ACELRX PHARMACEUT. DL-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's total liabilities have evolved over time, based on quarterly financial data.
ACELRX PHARMACEUT. DL-01 Competitors by Total Liabilities
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inventus Mining Corp
V:IVS
|
Canada | CA$1.14 Million |
|
Cassiar Gold Corp
V:GLDC
|
Canada | CA$4.99 Million |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
USA | $40.18 Million |
|
Incross Co. Ltd
KQ:216050
|
Korea | ₩123.08 Billion |
|
S H L Telemedicine Ltd
SW:SHLTN
|
Switzerland | CHF40.82 Million |
|
RS GROUP PLC
LSE:RS1
|
UK | GBX1.27 Billion |
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
USA | $418.60 Million |
|
Youlife Group Inc. American Depositary Shares
NASDAQ:YOUL
|
USA | $489.61 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ACELRX PHARMACEUT. DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of ACELRX PHARMACEUT. DL-01.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACELRX PHARMACEUT. DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual total liabilities of ACELRX PHARMACEUT. DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €12.68 Million ≈ $14.83 Million |
+23.93% |
| 2024-12-31 | €10.23 Million ≈ $11.97 Million |
+62.72% |
| 2023-12-31 | €6.29 Million ≈ $7.35 Million |
-75.50% |
| 2022-12-31 | €25.67 Million ≈ $30.01 Million |
-77.44% |
| 2021-12-31 | €113.79 Million ≈ $133.03 Million |
-- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more